Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
Characterization of the OSGIN1 gene
Oxidative stress induced growth inhibitor 1 (OSGIN1), also named bone marrow stromal cell (BMSC)-derived growth inhibitor 1 (BDG1) or ovary, kidney and liver protein 38 (OKL38), was first identified in 2001 as a novel induced pregnancy complementary DNA (cDNA) from a human ovary cDNA library. Huynh et al. originally named the gene OKL38 based on the predominant expression of its protein product in ovary, kidney and liver and its predicted size of about 38 kDa. Nevertheless, additional aliases arose from identification of different isoforms of this gene that resulted in the discovery of a 52 kDa and a 61 kDa protein product from the same gene.
OSGIN1 balances cell growth, differentiation and death
OSGIN1 was originally identified as a novel pregnancy gene. Studies by Huynh et al. localized OSGIN1 to rat breast epithelial cells and found that it was induced during pregnancy and lactation. Further analysis of OSGIN1 in human breast cancer cell lines found that expression of the protein was abnormally low in these cells. Interestingly, the researchers found that OSGIN1 overexpression reduced tumor formation in these mice, indicating that this protein could play an important role in the differentiation and growth of cells. Further studies by Ong et al. found that overexpression of the 52 kDa OSGIN1 isoform protein may also inhibit cell proliferation, induce cell death and reduce the migration of various cancer cell lines.
Further investigation into the specific pathways associated with OSGIN1 mediated cell cycle regulation found that OSGIN1 specifically induces cell cycle arrest in the S phase resulting in the induction of apoptosis in breast cancer cells. Yao et al. expanded upon these findings in experiments involving DNA damage and confirmed that OSGIN1 regulates apoptosis through mitochondrial localization and cytochrome C release that involves the transcriptional control of tumor suppressor protein (p53) and peptidyl arginine deiminase 4 (PADI4) (Figure 1). In these studies, p53 and OSGIN1 levels were found to be repressed before DNA damage which correlated with high PADI4 expression at the OSGIN1 promoter. In contrast, increased DNA damage leads to increased p53 at the OSGIN1 promoter, increased OSGIN1 expression and suppression of PADI4. Together, PADI4 and p53 could alternately regulate the expression of OSGIN1 to mediate apoptosis during periods of cell damage (Figure 1).
Figure 1. Regulation of OSGIN1.
OSGIN1 and disease
A large number of data supporting OSGIN1 as a regulator of cell cycle stems from studies investigating tumorigenesis. Some of the first investigations of OSGIN1 found OSGIN1 to be down-regulated in 70% of kidney tumors using cancer gene profiling arrays. These findings were also paralleled in hepatocellular carcinoma (HCC) where the loss of OSGIN1 correlated with advanced tumor stages of HCC.
Many studies investigating the importance of OSGIN1 in tumorigenesis have been conducted using breast cancer cell lines. As previously mentioned, OSGIN1 was originally identified as an important gene regulated during pregnancy and is believed to contribute to mammary gland cell growth and death needed during stages of lactation. This role suggests that fluctuations in the OSGIN1 gene may be required for the cellular changes that transition a cell from a normal to a malignant state. The fluctuations of OSGIN1 in breast cells contrasts with the more stable expression of this gene in other tissue types, suggesting dysregulation of OSGIN1 in this tissue type may be causative of disease. Global gene expression profiling conducted on cancer cells treated with Taheebo identified cell growth arrest and initiation of apoptosis in these cells to be correlated with increased OSGIN1 expression. These studies suggest OSGIN1 as a tumor suppressor and thus a potential therapeutic target in cancer.
Less investigation has been conducted on the role of OSGIN1 in non-carcinogenic diseases; nevertheless, some studies target OSGIN1 as regulated during models of cardiovascular disease. Exposure to ultrafine particles (UFP), associated with ambient air pollution, has been shown to be associated with cardiovascular disease. Microarray studies showed OSGIN1 to be upregulated upon exposure to diesel exhaust particles which can adversely affect health. These findings were confirmed in a study by Li et al in 2010 that showed that UFP induced superoxide and resulted in increased OSGIN1 expression in human aortic endothelial cells (HAEC). Further research is necessary to understand the role of OSGIN1 in cardiovascular disease as well as other unstudied diseases.
References:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.